Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Mineralys Therapeutics, Inc.'s lorundrostat shows promise for treating aldosterone-driven hypertension with FDA approval by ...

Infections caused by herpes simplex virus type 1 (HSV-1) can lead to HSV-1 encephalitis—a rare but deadly condition that ...

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate ...

Asandeutertinib is a derivative of Tagrisso designed to avoid certain toxic side effects in patients with EGFR-mutated NSCLC.

Discover 7 treatments for ischemic heart disease that are saving lives. From cutting-edge medications to advanced procedures ...

DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

RIP-1) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, inflammatory bowel disease, psoriasis, rheumatoid arthritis, multiple sclerosis, stroke, Alzheimer’s disease ...

Here we have applied a general strategy, inverse design using the substrate envelope, to develop inhibitors of HIV-1 protease. Structure-based computation was used to design inhibitors predicted to ...

Chengdu Zeling Biomedical Technology Co. Ltd. has described poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment cancer.